B
Bull
Bull · 25%PPBT
$2.79
Szenariopreis
$1.680
+0.020 (+1.20%)Zum Schluss
Loading chart…
- High
- 1.800
- Open
- 1.790
- VWAP
- 1.71
- Vol
- 38.36K
- Mkt Cap
- 11.43M
- Low
- 1.660
- Amount
- 65.72K
- EV/EBITDA, TTM
- 0.00
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
AI analysis of Purple Biotech Ltd (PPBT)
buyPurple Biotech Ltd is a good buy right now due to its recent positive momentum and potential for recovery. The current price is $1.68, and the stock has shown a 20% increase over the last 20 days, indicating a positive trend. Additionally, the RSI is at 66.188, suggesting that the stock is nearing overbought territory but still has room for growth. The main risk is the significant operating loss reported in Q2 2026, which totaled $2.1 million, indicating ongoing financial challenges that could impact future performance.
Bewertungskennzahlen
The current forward P/E ratio for Purple Biotech Ltd (PPBT) is 0.00, compared to its 5-year average forward P/E of -7.40.
Alphio AI Price Scenarios for PPBT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.506-11NewsfilterPurple Biotech's IM1240 Study Advances with Promising Results
9.505-15seekingalphaPurple Biotech Reports Q1 2026 Financial Results
9.004-23moomooPURPLE BIOTECH LTD FORMS SCIENTIFIC ADVISORY BOARD FOR CAPTN-3 ANTIBODY PLATFORM
7.503-25moomooPurple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI
- 8.503-17seekingalpha
Purple Biotech Regains Nasdaq Compliance
PPBT FAQ — answered by Alphio AI
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Purple Biotech Ltd is a good buy right now due to its recent positive momentum and potential for recovery. The current price is $1.68, and the stock has shown a 20% increase over the last 20 days, indicating a positive trend. Additionally, the RSI is at 66.188, suggesting that the stock is nearing overbought territory but still has room for growth. The main risk is the significant operating loss reported in Q2 2026, which totaled $2.1 million, indicating ongoing financial challenges that could impact future performance.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.